RAPP — Rapport Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2012593 ·
Last close
$33.91
Market Cap
$1.63B
52W High
$52.93
52W Low
$23.75
ADV30
388,840
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -60,806,000 | -56,615,000 | 458,982,000 | 63,612,000 | 36,056,000 |
| Mar 2026 | 20,000,000 | — | -24,215,000 | -19,857,000 | 497,597,000 | 78,056,000 | 26,085,000 |
| Dec 2025 | 0 | — | -38,509,000 | -33,763,000 | 512,431,000 | 52,645,000 | 27,778,000 |
| Sep 2025 | 0 | — | -29,986,000 | -26,925,000 | 535,323,000 | 251,359,000 | 23,706,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-96,682,000
Investing CF
$-167,559,000
Financing CF
$272,786,000
CapEx
$-467,000
Dividends Paid
—
Buybacks
$-5,000
EPS Diluted TTM
$-3.04
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-311,700,000
Inventory
—
Receivables
$293,000
ST Investments
$372,465,000
EBIT TTM
$-153,516,000
Pretax Income TTM
$-137,160,000
Interest Exp TTM
—
Analysts
12
Yahoo Snapshot (yfinance, live)
Total Revenue
$20,000,000
EBITDA
$-152,556,000
Free Cash Flow
$-56,016,500
Enterprise Value
$1,666,840,832
Total Cash
$436,076,992
Total Debt
$10,105,000
Shares Out
47,978,286
Trailing EPS
$-3.03
Book Value
$8.82
ROE
-40.0%
ROA
-25.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -125,099,000 | -111,483,000 | 512,431,000 | 27,778,000 | 484,653,000 | -87,473,000 |
| Dec 2024 | 0 | -83,055,000 | -78,307,000 | 314,933,000 | 9,506,000 | 305,427,000 | -64,828,000 |
| Dec 2023 | 0 | -36,179,000 | -34,786,000 | 155,423,000 | 181,057,000 | -25,634,000 | -27,181,000 |
| Dec 2022 | — | — | — | 31,603,000 | 41,665,000 | -10,062,000 | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-5.23
Max Pain — expiry 2026-11-20
max pain strike: $40.00 · spot: $32.99 · call oi: 1,907 · put oi: 3,579
Expected Move to 2026-11-20:
±$11.90
(36.07%) —
implied range
$21.09 –
$44.89
· ATM straddle on $32.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SNDX | Syndax Pharmaceuticals Inc | $1.63B | $18.20 | — |
| GHRS | GH Research PLC | $1.64B | $23.84 | — |
| ETON | Eton Pharmaceuticals, Inc. | $1.65B | $57.68 | — |
| STOK | Stoke Therapeutics, Inc. | $1.60B | $24.80 | — |
| XERS | Xeris Biopharma Holdings, Inc. | $1.66B | $9.10 | — |
News headlines (Yahoo Finance, 1h cache)
The Biggest Losers In Biotech — And It Had Nothing To Do With 'Compelling,' 'Best-In-Disease' Data
2026-09-23 20:12 · Yahoo
The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte
2026-09-23 12:37 · Yahoo
Rapport Therapeutics to Participate in Upcoming Investor Conferences
2026-09-02 11:00 · Yahoo
Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program
2026-08-24 11:00 · Yahoo
Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update
2026-08-05 11:00 · Yahoo
What Does the Sale of Rapport Therapeutics Stock Worth Over $400,000 by the Chief Operating Officer Mean for Investors?
2026-07-12 23:53 · Yahoo
Is Rapport Therapeutics (RAPP) Using RAP-219 To Redefine Its Broader Neuroscience Investment Narrative?
2026-06-08 02:08 · Yahoo
BTIG Raises its Price Target on Rapport Therapeutics (RAPP)
2026-06-05 21:03 · Yahoo
Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference
2026-05-20 20:05 · Yahoo
Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update
2026-05-07 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.